Blood glucose regulation via delayed gastric emptying and improved insulin sensitivity

This entry refers to the integrated physiological process of **regulating blood glucose levels** by **delaying gastric emptying** (thereby slowing the rate of glucose absorption) and **improving insulin sensitivity** (enabling more effective glucose uptake into tissues)[1][2][3]. Delayed gastric emptying is mediated through neurohormonal feedback involving peptides such as **glucagon-like peptide 1 (GLP-1)** and **glucose-dependent insulinotropic peptide (GIP)**, which act to slow gastric emptying and stimulate insulin release[1]. Drugs such as GLP-1 receptor agonists and pramlintide exploit this mechanism therapeutically in diabetes mellitus. However, this entry is not itself a canonical therapeutic target but a summary of therapeutic strategies targeting blood glucose through gastrointestinal and insulin pathways[1][2][3]. **Important caveat:** This "target" does not align with the format of a single molecular entity such as a receptor, enzyme, or transporter. Instead, it is a summary of mechanisms for glycemic control, and thus should not be listed as a discrete drug target.

Delaying gastric emptying to slow glucose absorption[2][3] Stimulating insulin secretion (e.g., via incretins such as GLP-1)[1][2] Inhibiting glucagon secretion[1] Enhancing insulin sensitivity